ASND Stock Analysis: Buy, Sell, or Hold?
ASND - Ascendis Pharma A/S American Depositary Shares
$243.91
-7.16 (-2.85%)
▼
5d:
-3.92%
30d:
-8.92%
90d:
+6.33%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
3d
Get Alerted When ASND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ASND trading at deep discount. Market pricing in -5.1% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ASND trading at deep discount. Market pricing in -5.1% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$146.28
Based on -8.4% avg growth
INTRINSIC VALUE TODAY
$90.83
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ASND is currently trading at $243.91, which is considered oversold relative to its 30-day fair value range of $250.95 to $269.90. From a valuation perspective, the stock is trading at a discount (Forward PE: 26.3) compared to its historical average (30.7). Remarkably, the market is currently pricing in an annual earnings decline of 5.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ASND is in a uptrend. The price is currently testing key support at $243.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $307.92 (+26.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ASND is in a uptrend. The price is currently testing key support at $243.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $307.92 (+26.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$250.95 -
$269.90
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 26.2% below Wall St target ($307.92)
Trading Range Analysis
30-Day Trading Range
$250.95 -
$269.90
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$243.30
Resistance Level
$263.26
Current Trend
Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.27
Wall Street Target
$307.92
(+26.2%)
Revenue Growth (YoY)
144.3%
Profit Margin
57.3%
Valuation Discount vs History
-5.1% cheaper
PE vs Historical
26.3 vs 30.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.1%
(market-implied from PE analysis)
1-Year Target
$231.47
(-5%)
2-Year Target
$219.67
(-10%)
3-Year Target
$208.46
(-15%)
3-Yr Target (if PE normalizes)
(PE: 26→31)
$243.63
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.3, Growth: -20.8%)
$177.81
(+-27%)
Base:
(SPY PE: 20.7, Growth: -20.8%)
$140.32
(-43%)
Bear:
(PE: 17.6, Growth: -20.8%)
$119.27
(-51%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (29x PE), but valuation improves significantly next year (26x PE) as earnings recover.
Trailing PE: 29.23 | Current EPS (TTM): $8.59
Bull Case
$298.53
(+22%)
Analyst growth 8.1%, PE expands to 32.2
Base Case
$271.39
(+11%)
Market implied 8.1%, PE stable at 29.2
Bear Case
$170.73
(-30%)
Severe decline -20.0%, PE contracts to 24.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 26.3 to 30.7
Stabilization Target:
$285.06
(+16.9%)
PE Expansion Potential:
+16.9%
Share & Embed Analysis
Last updated: August 02, 2026 12:47 PM ET
Data refreshes hourly during market hours. Next update: 1:47 PM
Data refreshes hourly during market hours. Next update: 1:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 54 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 60 HOLD |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$108 | 60 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$26 | 59 HOLD |
